Pharma Tech Trends and Development Cost Solutions
News Apr 04, 2013
The free webinar lays out the pressures currently being faced by the industry—including cost and regulatory pressures—and explores the chemistry workflows and emerging technologies that are helping industry participants address these challenges, remain competitive, and protect profits.
With the reality of patent cliffs, regulatory standards, attrition, and globalization, companies are learning to work fast and “lean” without sacrificing effectiveness and safety. In the webinar, targeted technology application and the methodologies it enables results in an ability to handle increased experiment volume—the kind that will be required for success if pharmaceutical industry trends continue—while lowering development and production costs.
Accounting for issues such as inherited chemistry, variable yields, and long development cycles, the webinar looks at real-world examples of industry giants such as Pfizer using technologies that help understand particle and reaction characteristics for significant process enhancement. In situ mid-IR spectroscopy and Focus Beam Reflectance Measurement (FBRM®)—as well as workstations that incorporate them—are shown to illuminate particle growth/crystallization and other critical reaction characteristics to shorten cycle times, increase yields, enhance safety, and ease scale-up. One production initiation example lowered costs by at least $.5M—a savings that will compound with each successive use of the equipment.
Reaction Progress Kinetics Analysis is also discussed in detail. This methodology, developed by Professor Donna Blackmond who is currently with Scripps Research Institute, allowed researchers to develop a kinetic model in significantly fewer experiments over traditional methods, which in turn helped optimize a synthetic route for enhanced commercial viability.
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE
British Pharmacological Society’s Drug Discovery of the Year 2018 AnnouncedNews
A new medicine used to treat an ultra-rare inherited disorder which leaves babies without a fully functioning immune system has been named the British Pharmacological Society’s Drug Discovery of the Year 2018.READ MORE